Cargando…
Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study
OBJECTIVE: To examine whether metformin use was associated with knee cartilage volume loss over 4 years and risk of total knee replacement over 6 years in obese individuals with knee osteoarthritis. METHODS: This study analysed the Osteoarthritis Initiative participants with radiographic knee osteoa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534888/ https://www.ncbi.nlm.nih.gov/pubmed/31126352 http://dx.doi.org/10.1186/s13075-019-1915-x |
_version_ | 1783421502370086912 |
---|---|
author | Wang, Yuanyuan Hussain, Sultana Monira Wluka, Anita E. Lim, Yuan Z. Abram, François Pelletier, Jean-Pierre Martel-Pelletier, Johanne Cicuttini, Flavia M. |
author_facet | Wang, Yuanyuan Hussain, Sultana Monira Wluka, Anita E. Lim, Yuan Z. Abram, François Pelletier, Jean-Pierre Martel-Pelletier, Johanne Cicuttini, Flavia M. |
author_sort | Wang, Yuanyuan |
collection | PubMed |
description | OBJECTIVE: To examine whether metformin use was associated with knee cartilage volume loss over 4 years and risk of total knee replacement over 6 years in obese individuals with knee osteoarthritis. METHODS: This study analysed the Osteoarthritis Initiative participants with radiographic knee osteoarthritis (Kellgren-Lawrence grade ≥ 2) who were obese (body mass index [BMI] ≥ 30 kg/m(2)). Participants were classified as metformin users if they self-reported regular metformin use at baseline, 1-year and 2-year follow-up (n = 56). Non-users of metformin were defined as participants who did not report the use of metformin at any visit from baseline to 4-year follow-up (n = 762). Medial and lateral cartilage volume (femoral condyle and tibial plateau) were assessed using magnetic resonance imaging at baseline and 4 years. Total knee replacement over 6 years was assessed. General linear model and binary logistic regression were used for statistical analyses. RESULTS: The rate of medial cartilage volume loss was lower in metformin users compared with non-users (0.71% vs. 1.57% per annum), with a difference of − 0.86% per annum (95% CI − 1.58% to − 0.15%, p = 0.02), after adjustment for age, gender, BMI, pain score, Kellgren-Lawrence grade, self-reported diabetes, and weight change over 4 years. Metformin use was associated with a trend towards a significant reduction in risk of total knee replacement over 6 years (odds ratio 0.30, 95% CI 0.07–1.30, p = 0.11), after adjustment for age, gender, BMI, Kellgren-Lawrence grade, pain score, and self-reported diabetes. CONCLUSIONS: These data suggest that metformin use may have a beneficial effect on long-term knee joint outcomes in those with knee osteoarthritis and obesity. Randomised controlled trials are needed to confirm these findings and determine whether metformin would be a potential disease-modifying drug for knee osteoarthritis with the obese phenotype. |
format | Online Article Text |
id | pubmed-6534888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65348882019-05-30 Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study Wang, Yuanyuan Hussain, Sultana Monira Wluka, Anita E. Lim, Yuan Z. Abram, François Pelletier, Jean-Pierre Martel-Pelletier, Johanne Cicuttini, Flavia M. Arthritis Res Ther Research Article OBJECTIVE: To examine whether metformin use was associated with knee cartilage volume loss over 4 years and risk of total knee replacement over 6 years in obese individuals with knee osteoarthritis. METHODS: This study analysed the Osteoarthritis Initiative participants with radiographic knee osteoarthritis (Kellgren-Lawrence grade ≥ 2) who were obese (body mass index [BMI] ≥ 30 kg/m(2)). Participants were classified as metformin users if they self-reported regular metformin use at baseline, 1-year and 2-year follow-up (n = 56). Non-users of metformin were defined as participants who did not report the use of metformin at any visit from baseline to 4-year follow-up (n = 762). Medial and lateral cartilage volume (femoral condyle and tibial plateau) were assessed using magnetic resonance imaging at baseline and 4 years. Total knee replacement over 6 years was assessed. General linear model and binary logistic regression were used for statistical analyses. RESULTS: The rate of medial cartilage volume loss was lower in metformin users compared with non-users (0.71% vs. 1.57% per annum), with a difference of − 0.86% per annum (95% CI − 1.58% to − 0.15%, p = 0.02), after adjustment for age, gender, BMI, pain score, Kellgren-Lawrence grade, self-reported diabetes, and weight change over 4 years. Metformin use was associated with a trend towards a significant reduction in risk of total knee replacement over 6 years (odds ratio 0.30, 95% CI 0.07–1.30, p = 0.11), after adjustment for age, gender, BMI, Kellgren-Lawrence grade, pain score, and self-reported diabetes. CONCLUSIONS: These data suggest that metformin use may have a beneficial effect on long-term knee joint outcomes in those with knee osteoarthritis and obesity. Randomised controlled trials are needed to confirm these findings and determine whether metformin would be a potential disease-modifying drug for knee osteoarthritis with the obese phenotype. BioMed Central 2019-05-24 2019 /pmc/articles/PMC6534888/ /pubmed/31126352 http://dx.doi.org/10.1186/s13075-019-1915-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wang, Yuanyuan Hussain, Sultana Monira Wluka, Anita E. Lim, Yuan Z. Abram, François Pelletier, Jean-Pierre Martel-Pelletier, Johanne Cicuttini, Flavia M. Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study |
title | Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study |
title_full | Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study |
title_fullStr | Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study |
title_full_unstemmed | Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study |
title_short | Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study |
title_sort | association between metformin use and disease progression in obese people with knee osteoarthritis: data from the osteoarthritis initiative—a prospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534888/ https://www.ncbi.nlm.nih.gov/pubmed/31126352 http://dx.doi.org/10.1186/s13075-019-1915-x |
work_keys_str_mv | AT wangyuanyuan associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT hussainsultanamonira associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT wlukaanitae associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT limyuanz associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT abramfrancois associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT pelletierjeanpierre associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT martelpelletierjohanne associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy AT cicuttiniflaviam associationbetweenmetforminuseanddiseaseprogressioninobesepeoplewithkneeosteoarthritisdatafromtheosteoarthritisinitiativeaprospectivecohortstudy |